The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome

günendi, zafer; Tecer, Duygu; Gogus, Feride; Büyükşireci, Dilek

doi:10.4274/gulhane.galenos.2020.1070

The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome

Duygu TECER, (Sağlık Bilimleri Üniversitesi Türkiye, Gülhane Eğitim ve Araştırma Hastanesi, Romatoloji Kliniği, Ankara, Türkiye)

Dilek Eker BÜYÜKŞİRECİ, (Hitit Üniversitesi, Erol Olçok Eğitim ve Araştırma Hastanesi, Fiziksel Tıp ve Rehabilitasyon Kliniği, Çorum, Türkiye)

Zafer GÜNENDİ, (Gazi Üniversitesi Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Romatoloji Anabilim Dalı, Ankara, Türkiye)

Feride GÖGÜŞ (Gazi Üniversitesi Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Romatoloji Anabilim Dalı, Ankara, Türkiye)

Gülhane Tıp Dergisi

2 0

Yıl: 2020 Cilt: 62 Sayı: 4 Sayfa Aralığı: 272 - 277 Metin Dili: İngilizce DOI: 10.4274/gulhane.galenos.2020.1070 İndeks Tarihi: 16-06-2021

The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome

Öz:

Aims: The aim of the this study is to evaluate beta-2-microglobulin (B2M) levels in patients with primary Sjögren’s syndrome (pSS) and to investigate their correlation with serum biomarkers and disease activity indexes commonly used in daily clinical practice.Methods: Eighty-one patients with pSS were included in this retrospective and cross-sectional study. Demographic data, clinical characteristics, B2M, immunoglobulin (Ig) A, IgG, IgM, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum complement (C) 3 and C4 levels, anti-nuclear antibody, rheumatoid factor (RF), anti-SSA and anti-SSB antibodies were obtained from the medical records. Disease activity was evaluated by the European League Against Rheumatism (EULAR) SS Disease Activity Index (ESSDAI) and EULAR SS Patients Reported Index (ESSPRI). Results: Serum B2M level was significantly higher in patients with anti-SSA and anti-SSB antibody (median: 2.64 mg/dL, minimum: 2.02 mg/dL, maximum: 10.10 mg/dL) than in only anti-SSA positive patients (median: 2.31 mg/dL, minimum: 1.33 mg/dL, maximum: 4.26 mg/dL, p=0.010) and both antibody negative patients (median: 1.80 mg/dL, minimum: 1.20 mg/dL, maximum: 2.65 mg/dL, p<0.001). Also, patients with anti-SSA antibody have significantly higher serum B2M levels than anti-SSA and anti-SSB antibodies negative patients (p=0.009). Serum B2M level was significantly correlated with ESSDAI (r=0.482, p=0.001), serum IgG level (r=0.374, p=0.001), IgA level (r=0.341, p=0.002), RF levels (r=0.412, p=0.021) and ESR (r=0.239, p:0.031). There was no correlation between ESSPRI, IgM, CRP and serum B2M levels. ESSDAI was not correlated with C3 (r=0.044, p=0.697), C4 (r=-0.053, p=0.640), ESR (r=0.111, p=0.326), CRP (r=0.111, p=0.324) and IgG (r=0.154, p=0.169).Conclusions: Although serum B2M levels were higher in autoantibody positive patients, it has a weak correlation with clinical disease activity.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Ferro F, Marcucci E, Orlandi M, Baldini C, Bartoloni-Bocci E. One year in review 2017: primary Sjogren’s syndrome. Clin Exp Rheumatol. 2017;35:179-191.
2. Fox RI. Sjogren’s syndrome. Lancet. 2005;366:321-331.
3. Barone F, Colafrancesco S. Sjogren’s syndrome: from pathogenesis to novel therapeutic targets. Clin Exp Rheumatol. 2016;34(Suppl 4):58-62.
4. Goules AV, Tzioufas AG. Primary Sjogren’s syndrome: clinical phenotypes, outcome and the development of biomarkers. Immunol Res. 2017;65:331-344.
5. Brito-Zeron P, Theander E, Baldini C, et al. Early diagnosis of primary Sjogren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol. 2016;12:137-156.
6. Chiou SJ, Chen CH. Decipher beta2-microglobulin: gainor loss-of-function (a mini-review). Med Sci Monit Basic Res. 2013;19:271-273.
7. Argyropoulos CP, Chen SS, Ng YH, et al. Rediscovering beta-2 microglobulin as a biomarker across the spectrum of kidney diseases. Front Med (Lausanne). 2017;4:73.
8. Yeung CK, Wong KL, Wong WS, Chan KH. Beta 2-microglobulin and systemic lupus erythematosus. J Rheumatol. 1986;13:1053-1058.
9. Yang J, Qian J, Wezeman M, et al. Targeting beta2- microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006;10:295- 307.
10. Yilmaz B, Koklu S, Yuksel O, Arslan S. Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease. World J Gastroenterol. 2014;20:10916-10920.
11. Pertovaara M, Korpela M, Uusitalo H, et al. Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both). Ann Rheum Dis. 1999;58:423-427.
12. Pertovaara M, Korpela M, Kouri T, Pasternack A. The occurrence of renal involvement in primary Sjogren’s syndrome: A study of 78 patients. Rheumatology (Oxford). 1999;38:1113-1120.
13. Pertovaara M, Korpela M, Pasternack A. Factors predictive of renal involvement in patients with primary Sjogren’s syndrome. Clin Nephrol. 2001;56:10-18.
14. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjogren’s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis. 2001;60:467-472.
15. Pertovaara M, Korpela M, Saarelainen S, et al. Longterm follow-up study of pulmonary findings in patients with primary Sjogren’s syndrome. Scand J Rheumatol. 2004;33:343-348.
16. Michalski JP, Daniels TE, Talal N, Grey HM. Beta2 microglobulin and lymphocytic infiltration in Sjogren’s syndrome. N Engl J Med. 1975;293:1228-1231.
17. Hatron PY, Wallaert B, Gosset D, et al. Subclinical lung inflammation in primary Sjogren’s syndrome. Relationship between bronchoalveolar lavage cellular analysis findings and characteristics of the disease. Arthritis Rheum. 1987;30:1226-1231.
18. Lahdensuo A, Korpela M. Pulmonary findings in patients with primary Sjogren’s syndrome. Chest. 1995;108:316-319.
19. Gottenberg JE, Busson M, Cohen-Solal J, et al. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren’s syndrome. Ann Rheum Dis. 2005;64:1050-1055.
20. Pertovaara M, Korpela M. Serum beta2 microglobulin correlates with the new ESSDAI in patients with Sjogren’s syndrome. Ann Rheum Dis. 2011;70:2236-2237.
21. Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren’s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One. 2013;8:e59868.
22. Pertovaara M, Parkkila S, Korpela M. Anti-carbonic anhydrase autoantibodies and serum beta-2 microglobulin correlate with the ClinESSDAI score in patients with Sjogren’s syndrome. Clin Exp Rheumatol. 2017;35:351.
23. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-558.
24. Seror R, Ravaud P, Mariette X, et al. EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Ann Rheum Dis. 2011;70:968-972.
25. Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren’s syndrome with EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2016;75:382-389.
26. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69:1103-1109.
27. Li L, Dong M, Wang XG. The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Chin Med J (Engl). 2016;129:448-455.
28. Yoo C, Yoon DH, Suh C. Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor. Blood Res. 2014;49:148-153.
29. Choe JY, Park SH, Kim SK. Urine beta2-microglobulin is associated with clinical disease activity and renal involvement in female patients with systemic lupus erythematosus. Lupus. 2014;23:1486-1493.
30. James K, Chipeta C, Parker A, et al. B-cell activity markers are associated with different disease activity domains in primary Sjogren’s syndrome. Rheumatology (Oxford). 2018;57:1222-1227.

APA	Tecer D, Büyükşireci D, günendi z, Gogus F (2020). The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome. , 272 - 277. 10.4274/gulhane.galenos.2020.1070
Chicago	Tecer Duygu,Büyükşireci Dilek,günendi zafer,Gogus Feride The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome. (2020): 272 - 277. 10.4274/gulhane.galenos.2020.1070
MLA	Tecer Duygu,Büyükşireci Dilek,günendi zafer,Gogus Feride The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome. , 2020, ss.272 - 277. 10.4274/gulhane.galenos.2020.1070
AMA	Tecer D,Büyükşireci D,günendi z,Gogus F The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome. . 2020; 272 - 277. 10.4274/gulhane.galenos.2020.1070
Vancouver	Tecer D,Büyükşireci D,günendi z,Gogus F The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome. . 2020; 272 - 277. 10.4274/gulhane.galenos.2020.1070
IEEE	Tecer D,Büyükşireci D,günendi z,Gogus F "The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome." , ss.272 - 277, 2020. 10.4274/gulhane.galenos.2020.1070
ISNAD	Tecer, Duygu vd. "The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome". (2020), 272-277. https://doi.org/10.4274/gulhane.galenos.2020.1070

APA	Tecer D, Büyükşireci D, günendi z, Gogus F (2020). The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome. Gülhane Tıp Dergisi, 62(4), 272 - 277. 10.4274/gulhane.galenos.2020.1070
Chicago	Tecer Duygu,Büyükşireci Dilek,günendi zafer,Gogus Feride The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome. Gülhane Tıp Dergisi 62, no.4 (2020): 272 - 277. 10.4274/gulhane.galenos.2020.1070
MLA	Tecer Duygu,Büyükşireci Dilek,günendi zafer,Gogus Feride The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome. Gülhane Tıp Dergisi, vol.62, no.4, 2020, ss.272 - 277. 10.4274/gulhane.galenos.2020.1070
AMA	Tecer D,Büyükşireci D,günendi z,Gogus F The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome. Gülhane Tıp Dergisi. 2020; 62(4): 272 - 277. 10.4274/gulhane.galenos.2020.1070
Vancouver	Tecer D,Büyükşireci D,günendi z,Gogus F The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome. Gülhane Tıp Dergisi. 2020; 62(4): 272 - 277. 10.4274/gulhane.galenos.2020.1070
IEEE	Tecer D,Büyükşireci D,günendi z,Gogus F "The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome." Gülhane Tıp Dergisi, 62, ss.272 - 277, 2020. 10.4274/gulhane.galenos.2020.1070
ISNAD	Tecer, Duygu vd. "The association of serum beta-2-microglobulin with autoantibody production and disease activity in patients with primary Sjögren’s syndrome". Gülhane Tıp Dergisi 62/4 (2020), 272-277. https://doi.org/10.4274/gulhane.galenos.2020.1070